Tema Oncology ETF (CANC) seeks to track companies developing cancer treatments and oncology-related technologies, focusing on pharmaceutical, biotechnology, and medical device firms advancing cancer research and therapeutics. This specialized healthcare ETF provides targeted exposure to the growing oncology market segment.

How It Works

CANC employs an actively managed approach, selecting companies based on their involvement in cancer treatment development, from early-stage research to commercialized therapies. The fund likely weights holdings based on market capitalization and oncology revenue exposure, with periodic rebalancing to maintain focus on pure-play cancer treatment companies. Holdings typically include large pharmaceutical companies with oncology divisions, specialized biotech firms, and medical technology companies developing cancer diagnostic and treatment equipment.

Key Features

  • Pure-play exposure to oncology sector, capturing growth from aging demographics and advancing cancer treatment technologies
  • Recently launched in August 2023, offering access to emerging cancer therapy companies and breakthrough treatment modalities
  • 2.38% dividend yield provides income from established pharmaceutical companies while maintaining growth exposure

Risks

  • This ETF can lose significant value if clinical trials fail or regulatory approvals are denied, as biotech stocks often decline 30-50% on negative drug development news
  • Concentrated sector exposure means the fund lacks diversification, making it vulnerable to healthcare regulation changes or sector-wide selloffs
  • High volatility typical of biotech investments could cause 20-40% swings during market uncertainty or FDA policy shifts

Who Should Own This

Best suited as a satellite holding (5-15% of portfolio) for aggressive growth investors with 3-7 year time horizons and high risk tolerance. Appropriate for those seeking thematic exposure to oncology innovation trends. Requires ability to withstand significant volatility while waiting for long-term drug development cycles to mature.

CANC chart by TradingView